The effectiveness of Spirulina platensis algae and N-acetyl cysteine for treatment of patients with COVID-19 infection

A clinical trial to compare the effectiveness of the Spirulina platensis algae (Arthrospira, blue-green algae) and N-acetyl cysteine with standard treatment in patients with COVID-19 infection

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220509054793N1

Enrollment

Registered

2022-06-02

Start date

2022-06-22

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with COVID-19 infection. COVID-19, virus identified

Interventions

Intervention 1: Intervention group I will receive 80 mg/kg/day Spirulina platensis algae along with standard treatment. Intervention 2: Intervention group II will receive 80 mg/kg/day Spirulina platen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with COVID-19 infection base on clinical manifestations, chest CT scan and PCR test results Age over 18 years The oxygen saturation of patient is 85 percent or greater at rest

Exclusion criteria

Exclusion criteria: having chronic lung disease Pregnant women Having autoimmune disease History of allergy to the seaweed or its derivatives History of bronchospasm after using of N-acetylcysteine Having chronic liver disease History of phenylketonuria Having bleeding (Massive hemoptysis, gastrointestinal bleeding, epistaxis, purpura, ecchymosis) Neutrophil count of less than 500 mmc A platelet count of less than 2000 mmc Having acute hepatitis

Design outcomes

Primary

Measure	Time frame
The duration of hospitalization. Timepoint: Two weeks after intervention. Method of measurement: The number days of hospitalization.;Improvement rate of clinical symptoms such as dyspnea and fever. Timepoint: Three months weeks after intervention. Method of measurement: Based on clinical examinations.;Possibility of hospitalization in ICU. Timepoint: Two weeks after intervention. Method of measurement: Need to receive intensive care in the patient.;Mortality rate. Timepoint: One month after intervention. Method of measurement: Calculating a mortality rate.	—

Measure

Time frame

The duration of hospitalization. Timepoint: Two weeks after intervention. Method of measurement: The number days of hospitalization.;Improvement rate of clinical symptoms such as dyspnea and fever. Timepoint: Three months weeks after intervention. Method of measurement: Based on clinical examinations.;Possibility of hospitalization in ICU. Timepoint: Two weeks after intervention. Method of measurement: Need to receive intensive care in the patient.;Mortality rate. Timepoint: One month after intervention. Method of measurement: Calculating a mortality rate.

—

Secondary

Measure	Time frame
Acute respiratory distress syndrome rate. Timepoint: Two weeks after intervention. Method of measurement: Patient with acute respiratory distress syndrome.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarid Poursadegh

Mashhad University of Medical Sciences

drpoursadeghf@gmail.com+98 51 3854 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026